Analysis of the lnfluence of Boron Distribution on CBE Values in Boron Neutron Capture Therapy [0.03%]
硼分布对BNCT中CBE值影响的分析
Zhiyuan Lin,Zuokang Lin,Zijian Zhang et al.
Zhiyuan Lin et al.
Boron Neutron Capture Therapy (BNCT) is an innovative cancer treatment that employs the 10B(n,α)7Li reaction to selectively destroy cancer cells at the cellular level. In BNCT, the biological effectiveness of boron doses is typically asses...
Protons versus Photons Postmastectomy Radiotherapy Effects on Breast Reconstruction Outcomes and Dosimetry Analysis [0.03%]
质子与光子-乳房切除术后放射治疗对重建效果及剂量的影响分析
George E Naoum,Katrina Dobinda,Amulya Yalamanchili et al.
George E Naoum et al.
Purpose: To compare the impact of proton versus photon postmastectomy radiation (PMRT) on implant related complications. Materials: The...
Intracranial disease control and survival among patients with KRAS-mutant lung adenocarcinoma and brain metastases treated with SRS [0.03%]
立体放射外科治疗KRAS突变型肺腺癌脑转移患者颅内控制和生存状况的研究
Benjamin Gaeta,Jordan E Eichholz,Henry Walch et al.
Benjamin Gaeta et al.
Background: Precision medicine according to molecularly defined subgroups offers great potential to improve outcomes for patients with metastatic lung adenocarcinoma. This study describes clinical outcomes and the impact ...
The Impact of Ultra-central Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: a Secondary Analysis of the Single-Arm Phase II SABR-5 Trial [0.03%]
肺寡转移瘤患者中超高中心肿瘤位置对预后影响的二次分析：SABR-5单臂二期临床试验结果分析
S Baker,C Leclerc,H Atmanspacher-Wirth et al.
S Baker et al.
Purpose/objectives: There is limited data on outcomes in patients with ultra-central pulmonary oligometastases treated with stereotactic ablative therapy (SABR). The purpose of this study was to determine whether ultra-ce...
A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR study [0.03%]
一项关于镭[223iran]和立体定向消融放射治疗寡转移性前列腺癌（前列腺癌骨寡转移）的II期临床试验：RadSABR研究
Jonathan Tward,Shane Lloyd,Skyler Johnson et al.
Jonathan Tward et al.
Purpose: We hypothesized that treatment with Radium223 (Ra223) and Stereotactic Ablative Radiotherapy (SABR) in patients with bone-only metachronous oligometastastic hormone-sensitive prostate cancer (moHSPC) could safely...
Concurrent and consolidative carboplatin plus nab-paclitaxel or paclitaxel in locally advanced NSCLC A multicenter, randomized clinical trial [0.03%]
卡铂联合纳米白蛋白结合型紫杉醇与普通紫杉醇同期及序贯治疗局部晚期NSCLC的多中心随机临床试验
Yuanyuan Zhang,Aaron M Laine,Puneeth Iyengar et al.
Yuanyuan Zhang et al.
Introduction: We investigated the efficacy and toxicity of thoracic radiotherapy (RT) plus concurrent and consolidation carboplatin with either solvent-based paclitaxel (sb-Paclitaxel) or solvent-free, nanoparticle albumi...
The Benefit of Short-Term Androgen Deprivation Therapy with Radiotherapy for Intermediate-Risk Prostate Cancer [0.03%]
短期雄激素剥夺治疗联合放疗治疗中危前列腺癌的利弊分析
Krishnan R Patel,Daniel E Spratt,Phouc T Tran et al.
Krishnan R Patel et al.
Introduction: A previous, individual patient-level meta-analysis of randomized controlled trials (RCTs) demonstrated the overall survival (OS) benefit of short-term androgen deprivation therapy (ST-ADT) when delivered wit...
Carbon ion radiotherapy with pencil beam scanning for stage III non-small cell lung cancer: toxicity profiles, survival outcomes, and prognostic indicators [0.03%]
分阶段III非小细胞肺癌的碳离子治疗（重离子治疗）笔形束扫描技术：毒性特征，生存结果和预后指标
Ningyi Ma,Xue Ming,Jian Chen et al.
Ningyi Ma et al.
Purpose: To evaluate the toxicities and survival outcomes associated with carbon ion radiotherapy (CIRT) using pencil beam scanning (PBS) and to assess the prognostic factors for patients with stage III non-small cell lun...
Ning Wen,Yibin Zhang,Haoran Zhang et al.
Ning Wen et al.
Purpose: The integration of advanced imaging and artificial intelligence (AI) technologies in radiotherapy has revolutionized cancer treatment by enhancing precision and adaptability. This study introduces a novel Dual En...
Patterns of relapse following radiotherapy of intermediate-risk (IR) prostate cancer (PCa) on the PROFIT randomized trial [0.03%]
PROFIT随机试验中接受放疗的中危前列腺癌(PCa)复发模式
M Langé,L Campion,L Ollivier et al.
M Langé et al.
Background: Conventionally fractionated radiotherapy (CFRT) and hypofractionated radiotherapy (HFRT) are established treatments for intermediate-risk (IR) prostate cancer (PCa), with differing dose per fraction. Yet, thei...